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ABSTRACT
CLN6 (Ceroid Lipofuscinosis, Neuronal, 6) is a 311-amino acid protein spanning the endoplasmic 
reticulum membrane. Mutations in CLN6 are linked to CLN6 disease, a hereditary neurodegenera-
tive disorder categorized into the neuronal ceroid lipofuscinoses. CLN6 disease is an autosomal 
recessive disorder and individuals affected with this disease have two identical (homozygous) or 
two distinct (compound heterozygous) CLN6 mutant alleles. Little has been known about CLN6’s 
physiological roles and the disease mechanism. We recently found that CLN6 prevents protein ag-
gregate formation, pointing to impaired CLN6’s anti-aggregate activity as a cause for the disease. 
To comprehensively understand the pathomechanism, overall anti-aggregate activity derived from 
two different CLN6 mutants needs to be investigated, considering patients compound heterozy-
gous for CLN6 alleles. We focused on mutant combinations involving the S132CfsX18 (132fsX) 
prematurely terminated protein, produced from the most frequent mutation in CLN6. The 132fsX 
mutant nullified anti-aggregate activity of the P299L CLN6 missense mutant but not of wild-type 
CLN6. Wild-type CLN6’s resistance to the 132fsX mutant was abolished by replacement of amino 
acids 297–301, including Pro297 and Pro299, with five alanine residues. Given that removal of 
CLN6’s C-terminal fifteen amino acids 297–311 (luminal tail) did not affect the resistance, we 
suggested that CLN6’s luminal tail, when unleashed from Pro297/299-mediated conformational 
constraints, is improperly positioned by the 132fsX mutant, thereby blocking the induction of anti- 
aggregate activity. We here reveal a novel mechanism for dissipating CLN6 mutants’ residual 
functions, providing an explanation for the compound heterozygosity-driven pathogenesis.
INTRODUCTION
CLN6 (Ceroid Lipofuscinosis, Neuronal, 6) is an 
endoplasmic reticulum (ER) protein and contains an 
N-terminal cytoplasmic domain, seven putative 
transmembrane domains, and a luminal C-terminus 
(Gao et al. 2002; Wheeler et al. 2002). Mutations in 
CLN6 are linked to the development of CLN6 dis-
ease, one type of the neuronal ceroid lipofuscinoses 
(NCLs), a group of hereditary neurodegenerative dis-
orders comprised of thirteen distinct types (Kollmann 
et al. 2013; Palmer et al. 2013; Warrier et al. 2013; 
Cárcel-Trullols et al. 2015; Mole et al. 2019; Butz 
et al. 2020; Nelvagal et al. 2020). CLN6 disease is 
characterized by seizures, motor difficulties, visual 
failure, and a shortened life-span, and is heteroge-
neous clinically and genetically, implying that CLN6’s 
functionality is differentially impaired among pa-
tients (Alroy et al. 2011). CLN6’s functions have 
been poorly understood, thereby making it difficult 
to assess the impacts of mutations in CLN6.
　We previously showed that tethering the small 
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combination with primers, named “Fwd” and “Rev” 
(Supporting Table 1). The PCR products were used 
as a template for the second-step PCR with follow-
ing primers sets, “132fsX”, “173fsX”, “239fsX” and 
“243fsX” (Supporting Table 2). Other Myc-tagged 
CLN6 mutants were generated with the pcDNA4/
Myc-wild-type CLN6 as a template in combination 
with primers described in Supporting Table 3. All 
the constructs were subjected to DNA sequencing. 
To generate pFLAG-CMV-5.1-wild-type CLN6 
(CLN6-FLAG) and pFLAG-CMV-5.1-P299L CLN6 
mutant (P299L-FLAG), pcDNA4/Myc-wild-type 
CLN6 or pcDNA4/myc-P299L CLN6 mutant were 
digested with HindIII/EcoRI and cloned in frame 
into the HindIII/EcoRI-digested pFLAG-CMV-5.1 
(Sigma-Aldrich).
Cell culture and transfection. HeLa cells were main-
tained in Dulbecco’s Modified Eagle Medium (nacalai 
tesque, Japan) supplemented with 10% fetal bovine 
serum at 37°C in a humidified cell culture incubator 
with 5% CO2. For transfection experiments in 24-
well plates, 1.5 × 104 HeLa cells were seeded per 
well in 0.5 mL of the cell growth medium 20 h be-
fore transfection. The cells in each well were trans-
fected with 1.2 μL of Polyethylenimine (PEI) “Max” 
(Polysciences) mixed with 0.4 μg of single or multi-
ple expression plasmids, where 0.2 μg each of two 
plasmids or 0.13 μg each of three plasmids were 
used. The transfection efficiency under these condi-
tions was approximately 80% in all experiments.
Immunoblotting assays. At 16 h post-transfection, 
HeLa cells were lysed with 1 × Laemmli sample buf-
fer (0.5 mM Tris-HCl (pH 6.8), 1.25% SDS, 12.5% 
glycerol, 1.25% 2-mercaptoethanol and 2.5% bro-
mophenol blue), then centrifuged at 14,800 rpm for 
5 min. The supernatant was collected, heated at 
95°C for 1 min, resolved by SDS-PAGE, and elec-
trotransferred onto polyvinylidene difluoride mem-
branes. Then, the membranes were incubated with 
antibodies against Actin (1 : 200 diluted; Santa Cruz 
Biotechnology, C-2, sc-8432) or Myc (1 : 200 dilut-
ed; Santa Cruz Biotechnology, 9E10, sc-40) or 
FLAG (1 : 4500 diluted; Cell Signaling Technology) 
for 8 h at 4°C. Afterwards, the membranes were 
incubated for 20 min with horseradish peroxidase 
(HRP)-conjugated antibodies (1 : 8000 diluted; rab-
bit anti-mouse IgG, DAKO or 1 : 8000 diluted; goat 
anti-rabbit IgG, DAKO). HRP on the membrane was 
detected using the ECL Advance luminescence solu-
tion (GE Healthcare Life Science) according to the 
manufacturer’s instruction.
heat shock protein αB-crystallin (αBC), which oth-
erwise is widely distributed throughout the cyto-
plasm, to the ER membrane suppresses aggregation 
of the myopathy-causing R120G αBC missense mu-
tant (Yamamoto et al. 2014), highly prone to aggre-
gate even when transfected into cell lines (Vicart et 
al. 1998). Subsequently, we isolated CLN6 as a 
binder to the ER-tethered αBC and revealed that 
CLN6 can prevent the R120G αBC mutant from ag-
gregating. These findings indicated that the R120G 
αBC mutant serves as a model protein in determin-
ing the anti-aggregate activity of CLN6 and its mu-
tants. Indeed, we demonstrated by employing the 
R120G αBC mutant that CLN6’s anti-aggregate ac-
tivity is compromised to various extents depending 
on which pathogenic mutation is introduced into 
CLN6 (Yamashita et al. 2017, 2020). The finding 
led us to propose that the difference in functionality 
among CLN6 mutants can be assessed based on 
their anti-aggregate activity. We have so far ana-
lyzed anti-aggregate activity in a cell line transfect-
ed with a single CLN6 mutant. The activity detected 
is most likely to correlate with that in a patient ho-
mozygous for the corresponding CLN6 mutant. On 
the other hand, in order to predict what happens in 
patients compound heterozygous for CLN6 mutants, 
the overall activity exhibited by two different CLN6 
mutants, but not the activity of each mutant, is re-
quired to be investigated.
　In this study, we show that the anti-aggregate ac-
tivity of one CLN6 mutant can be nullified by an-
other mutant, pointing to functional interference 
between CLN6 mutants as the pathomechanisms op-
erating in patients with CLN6 compound heterozy-
gosity. Our findings have provided novel insight into 
the molecular basis of clinical and genetic heteroge-
neity of CLN6 disease.
MATERIALS AND METHODS
Expression vectors. The construction of pEGFP-N1-
R120G αBC mutant (R120G αBC), pcDNA4/Myc-
wild-type CLN6 (WT) and DNA4/Myc-R106PfsX26 
CLN6 mutant (106fsX) was described previously 
(Yamamoto et al. 2014; Yamashita et al. 2017, 
2020). The DNA fragment corresponding to the 
S132CfsX18, D173EfsX33, F239PfsX29 and 
A243PfsX26 CLN6 frameshift mutants (hereafter re-
ferred to as 132fsX, 173fsX, 239fsX and 243fsX, 
respectively) were generated by sequential PCRs. 
The first-step PCR was conducted using PrimeSTAR 
Mutagenesis Basal Kit (TAKARA Bio) with the 
pcDNA4/Myc-wild-type CLN6 as a template in 
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acid stretch (Wheeler et al. 2002). Not only patients 
homozygous for the 132fsX mutant but also those 
compound heterozygous for this mutant have been 
described, among whom clinical manifestations are 
not consistent (Wheeler et al. 2002; Cannelli et al. 
2009). Structurally, the 132fsX mutant lacks CLN6’s 
third loop and beyond, the region required for 
CLN6’s anti-aggregate activity (Yamashita et al. 
2020). Collectively, the 132fsX mutant was expect-
ed to serve as an ideal tool with which to further 
explore the relationship between the disease hetero-
geneity and the reduction in CLN6’s anti-aggregate 
activity. We first determined if the 132fsX mutant 
suppresses aggregation of the R120G disease-caus-
ing αBC mutant, a model protein highly prone to 
aggregate. When transfected into HeLa cells, the 
EGFP-tagged R120G αBC mutant was visualized as 
a diffuse signal widely distributed throughout the 
cytoplasm (the mutant spared from aggregation) or 
as intracellular speckles (the aggregated mutant) 
(Yamamoto et al. 2014). Based on microscopic im-
ages, we calculated the proportion of aggregate-pos-
itive cells to EGFP-positive cells. Transfection of 
Myc-tagged wild-type CLN6 into HeLa cells low-
ered aggregate positivity by ~15% compared with 
controls employing the insertless vector expressing 
Myc alone (Fig. 1B–D). In contrast, the percentage 
of aggregate-positive cells was not significantly af-
fected upon transfection of the Myc-tagged 132fsX 
mutant, suggesting that the mutant lacks anti-aggre-
gate activity.
The 132fsX mutant nullified anti-aggregate activity 
of coexisting CLN6 mutants
The 132fsX mutant-involving compound heterozy-
gosity has been reported in four patients (Cannelli et 
al. 2009). Two of them have the 239fsX prematurely 
terminated protein, which arises from a 4-bp dele-
tion (c.715–718delTTCG) and corresponds to amino 
acids 1–238 of CLN6 followed by an irrelevant 
29-amino acid stretch (Cannelli et al. 2009) and the 
132fsX truncated mutant, and the other two the 
P299L CLN6 missense mutant (Sharp et al. 2003) 
and the 132fsX truncated mutant (Fig. 2A). Mean-
while, the 106fsX truncated mutant, which corre-
sponds to amino acids 1–105 of CLN6 followed by 
an irrelevant 26-amino acid stretch (Wheeler et al. 
2002), has been found only in homozygous patients 
(Fig. 2A). The 1-bp insertion (c.316insC) producing 
the 106fsX prematurely terminated protein is identi-
cal to that in the nclf mouse, a naturally-occurring 
mouse model of CLN6 disease (Bronson et al. 
1998; Gao et al. 2002; Wheeler et al. 2002; Kurze 
Immunoprecipitation assays. HeLa cells were solu-
bilized in lysis buffer (50 mM Tris (pH 8.0), 150 mM 
NaCl, 1% Nonidet P40 (NP-40), and protease inhib-
itor cocktail). Anti-FLAG antibody (Cell Signaling 
Technology) was added in the lysates and incubated 
for 15 min, and then protein A-Sepharose (GE 
Healthcare Life Sciences) was added and mixed by 
rotation for 15 min. Afterwards, protein A-Sepharose 
was collected and washed three times with lysis buf-
fer. Finally, 2 × Laemmli sample buffer was added 
in the samples and heated at 95°C for 1 min.
Measurement of aggregate positivity. To visualize 
the EGFP-tagged R120G αBC missense mutant, a 
fluorescence microscope IX-51 (Olympus, Japan) 
with 20×/0.40 NA dry objective was used. At 16 h 
post-transfection, HeLa cells expressing EGFP- 
tagged R120G αBC mutants were illuminated with 
the mercury light (U-LH100HGAPO). EGFP images 
were captured with a digital camera WRAYCAM- 
SR300 (WRAYMER, Japan) and WraySpect (WRAY-
MER, Japan). WRAYCAM-SR300 was used through 
0.35×c-mount lens. The EGFP-tagged R120G αBC 
mutant was observed as speckles of various size or 
as a diffuse signal widely distributed throughout the 
cytoplasm. A cell with speckle(s) was counted as an 
aggregate-positive cell, regardless of how large a 
speckle is and of how many speckles are found in 
the cell. The proportion of the aggregate-positive 
cells to the EGFP-positive cells was calculated and 
is shown as “Cells with aggregates (%).” At least 
800 cells were analyzed for each condition in every 
assay.
Statistical analysis. All data are expressed as means 
± S.E.M. The data was accumulated under each con-
dition from at least five independent experiments. 
For parametric all-pairs multiple comparisons in all 
figures, Tukey-test was used.
RESULTS
The 132fsX truncated mutant was unable to prevent 
the R120G αBC mutant’s aggregation
CLN6 disease is heterogeneous clinically and genet-
ically (Cannelli et al. 2009; Chin et al. 2019). In or-
der to investigate if the disease heterogeneity is 
associated with dysregulation of CLN6’s anti-aggre-
gate activity, we focused on the 132fsX prematurely 
terminated protein (Fig. 1A), which arises from a 
2-bp deletion (c.395–396delCT), the most common 
mutation in CLN6, and corresponds to amino acids 
1–131 of CLN6 followed by an irrelevant 18-amino 
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with the 239fsX and the 132fsX mutants was ~15% 
higher than that in the cells transfected with the 
239fsX mutant alone (Fig. 2D). Likewise, the P299L 
mutant’s anti-aggregate activity was attenuated upon 
coexpression of the 132fsX mutant. Both the 239fsX 
and the P299L mutants were similarly disabled by 
the 106fsX truncated mutant. Given that wild-type 
CLN6’s activity toward the R120G αBC mutant was 
not negatively impacted by the 106fsX or the 132fsX 
mutant (Fig. 2D), we suggested that these mutants 
et al. 2010). We previously demonstrated that the 
106fsX truncated mutant is unable to prevent the 
R120G αBC mutant from aggregating (Yamashita et 
al. 2020). In contrast with the 106fsX mutant, both 
the 239fsX and the P299L mutants inhibited the 
R120G αBC mutant’s aggregation comparably to 
wild-type CLN6 (Fig. 2B, C). The finding prompted 
us to assess if their anti-aggregate activity is affect-
ed by simultaneous expression of the 132fsX mu-
tant. Aggregate positivity in HeLa cells transfected 
Fig. 1　The inability of the 132fsX mutant to prevent the R120G αBC mutant’s aggregation. (A) Schematic representation 
of wild-type CLN6 (WT) and the 132fsX mutant. (B) HeLa cells were transfected with 0.4 μg each of the insertless vector 
(Ev), the Myc-tagged 132fsX mutant (132fsX)- or Myc-tagged wild-type CLN6 (WT)-expressing vector. The cells were lyzed 
16 h after transfection. Their lysates were separated by SDS-PAGE and electrotransferred to PVDF membranes for the sub-
sequent immunoblot analysis using the indicated antibodies. (C) HeLa cells were cotransfected with 0.2 μg of the expres-
sion construct encoding the EGFP-tagged R120G αBC mutant (R120G αBC-EGFP) in combination with 0.2 μg of either 
Ev, 132fsX- or WT-expressing vector. At 16 h post-transfection, the cells were examined by fluorescence microscopy to vi-
sualize the EGFP-tagged R120G αBC mutant. Shown are the images captured at this time point, where the EGFP-tagged 
R120G αBC mutant is observed as speckles of various size (aggregated) or as a diffuse signal widely distributed across 
the cytoplasm (spared from aggregation). Scale bars: 20 μm. (D) Based on the images in (C), a cell with speckle(s) was 
counted as an aggregate-positive cell, regardless of how large a speckle is and of how many speckles are found in the 
cell. The proportion of the aggregate-positive cells to the EGFP-positive cells was calculated and is shown as “Cells with 
aggregates (%).” At least 800 cells were analyzed for each condition in every assay. The data represent mean ± SEM of at 
least six independent experiments. * P < 0.05.
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mutants are prematurely terminated proteins; the 
former arises from a 1-bp deletion (c.519delT) and 
corresponds to amino acids 1–172 of CLN6 fol-
lowed by an irrelevant 33-amino acid stretch, and 
the latter arises from a 1-bp deletion (c.727delG) 
and corresponds to amino acids 1–242 of CLN6 fol-
lowed by an irrelevant 26-amino acid stretch. We 
thus investigated if these three truncated mutants 
differentially affect the P299L mutant’s anti-aggre-
gate activity. The P299L mutant, when expressed 
alone, suppressed the R120G αBC mutant’s aggre-
lacking CLN6’s third loop and beyond specifically 
counteract the coexisting CLN6 mutants.
The P299L mutant was selectively vulnerable to the 
132fsX truncated mutant
In CLN6 disease patients, the 239fsX mutant has 
been described solely in combination with the 132fsX 
mutant. On the other hand, the P299L mutant has 
been found together with the 132fsX, the 173fsX, or 
the 243fsX mutant (Fig. 3A) (Cannelli et al. 2009; 
Kousi et al. 2012). Both the 173fsX and the 243fsX 
Fig. 2　Disruption by the 132fsX mutant of anti-aggregate activity of both the 239fsX and the P299L mutants. (A) Sche-
matic representation of wild-type CLN6 (WT) and its mutants. (B) Immunoblot analysis performed as in Fig. 1(B). (C and D) 
Cells were transfected with the indicated combinations and amounts of expression vectors, and analyzed as in Fig. 1(C, D). 
The data represent mean ± SEM of six independent experiments. * P < 0.05.
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Integrity of CLN6’s amino acids 297–301 was re-
quired to resist the 132fsX mutant
The importance of proline in protein structure is 
widely accepted (DeTar et al. 1977). Given that mu-
tations of Pro297 and Pro299 in CLN6 have been 
described in patients (Sharp et al. 2003; Kousi et al. 
2012), these proline residues would serve to ensure 
CLN6’s structural integrity and consequently contrib-
ute to protection against the 132fsX mutant. We thus 
explored this idea by replacing amino acids 297–301 
in CLN6 with five alanine residues (Fig. 4A; 5A1). 
The 5A1 mutant, when expressed alone, suppressed 
the R120G αBC mutant’s aggregation (Fig. 4B, C). 
Its anti-aggregate activity, however, was attenuated 
gation, as shown by aggregate positivity of ~25% 
(Fig. 3B; Ev). The positivity was elevated by coex-
pression of the 106fsX or the 132fsX mutants, but 
not of the 173fsX or the 243fsX mutant. We thus 
reasoned that the P299L mutant is compromised 
only by truncated mutants that can physically inter-
act with the P299L mutant. This was not the case in 
fact. Coimmunoprecipitation assays showed that ev-
ery single truncated mutant employed here binds not 
only to the P299L mutant but also to wild-type CLN6 
(Fig. 3C). Taken together, we suggested that the 
P299L mutant is disabled preferentially by truncated 
mutants lacking CLN6’s third loop and beyond.
Fig. 3　The P299L mutant was disabled specifically by truncated mutants lacking CLN6’s third loop and beyond. (A) 
Schematic representation of wild-type CLN6 (WT) and its mutants. (B) Cells were transfected with the indicated combina-
tions and amounts of expression vectors, and analyzed as in Fig. 1(C, D). The data represent mean ± SEM of six indepen-
dent experiments. * P < 0.05. (C) Cells were transfected with 0.2 μg of the FLAG-tagged P299L mutant (P299L-FLAG) or 
FLAG-tagged wild-type CLN6 (WT-FLAG) in combination with 0.2 μg of the indicated Myc-tagged CLN6 truncated mutant. 
The whole cell lysates (Input) and the FLAG immunoprecipitates (IP: FLAG) were immunoblotted using antibodies against 
Myc or FLAG.
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properly positioned by the 132fsX mutant, thereby 
causing a failure to exert anti-aggregate activity. We 
thus tested our hypothesis using a CLN6 mutant 
lacking amino acids 297–311 (Fig. 5A; P297X). The 
P297X mutant not only displayed anti-aggregate ac-
tivity comparably to wild-type CLN6 but also was 
resistant to the coexisting 132fsX mutant (Fig. 5B–
D), arguing for our hypothesis. Collectively, we sug-
gested that a loss of a tight structural control over 
CLN6’s luminal tail underlies the vulnerability to 
the 132fsX mutant.
by the simultaneously expressed 132fsX mutant 
(Fig. 4D). In contrast, CLN6 mutants with the rest 
of the luminal tail replaced with alanine residues 
(Fig. 4A; 5A2 and 5A3) were refractory to the 
132fsX-mediated suppression (Fig. 4B–D), indicat-
ing that the amino acids 297–301 are key to CLN6’s 
resistance to the 132fsX mutant.
Removal of CLN6’s luminal tail resulted in insensi-
tivity to the 132fsX mutant
The mutational analysis noted above led us to hy-
pothesize that when unleashed from structural con-
straints imposed by the amino acids 297–301, 
CLN6’s luminal tail (amino acids 297–311) is im-
Fig. 4　Integrity of CLN6’s amino acids 297–301 conferred resistance to the 132fsX mutant. (A) Schematic representation 
of wild-type CLN6 (WT) and its mutants. (B) Immunoblot analysis performed as in Fig. 1(B). (C and D) Cells were trans-
fected with the indicated combinations and amounts of expression vectors, and analyzed as in Fig. 1(C, D). The data rep-
resent mean ± SEM of six independent experiments. * P < 0.05.
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al. 2003; Teixeira et al. 2003; Arsov et al. 2011; 
Kousi et al. 2012; Sun et al. 2018). It should be 
noted that mutations at both Pro297 and Pro299 
have been found in patients. The critical role that 
proline plays for protein structure has been well 
known (DeTar et al. 1977; Jing et al. 1998; Newbold 
et al. 2001). In contrast, the extent to which amino 
acid residues other than proline contribute to protein 
structure is not generalized. We expected that what 
the amino acids 297–301 provide is a structural ba-
sis for CLN6’s functionality, which would be estab-
lished chiefly by Pro297 and Pro299. Indeed, the 
P299L and the 5A1 mutants, when coexpressed with 
the 132fsX, became unable to display their intrinsic 
anti-aggregate activity, arguing for our idea. Further-
more, the P297X mutant, which lacks CLN6’s 
luminal tail (amino acids 297–311), exerted its anti- 
aggregate activity either with or without the 132fsX 
DISCUSSION
Both the P299L and the 5A1 mutants, when ex-
pressed alone, prevented aggregation of the R120G 
αBC mutant. These mutants’ anti-aggregate activity 
was, however, offset by the simultaneously ex-
pressed 132fsX mutant. Meanwhile, wild-type CLN6 
was not affected by the 132fsX mutant, indicating 
that integrity of CLN6’s amino acids 297–301 is vi-
tal to resisting the 132fsX mutant-driven interfer-
ence. The importance of this five-amino-acid stretch 
is also supported by genetic findings in patients. 
Within CLN6’s C-terminal thirty amino acids (282–
311), which follow the seventh transmembrane do-
main and face the ER lumen, six mutations have 
been found. All except one accumulate within ami-
no acids 297–301: Pro297Thr, Pro297LeufsX, 
Glu298Lys, Pro299Leu, and Trp300Arg (Sharp et 
Fig. 5　Removal of CLN6’s luminal tail resulted in insensitivity to the 132fsX mutant. (A) Schematic representation of wild-
type CLN6 (WT) and the P297X mutant. (B) Immunoblot analysis performed as in Fig. 1(B). (C and D) Cells were transfected 
with the indicated combinations and amounts of expression vectors, and analyzed as in Fig. 1(C, D). The data represent 
mean ± SEM of six independent experiments. * P < 0.05.
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nation within CLN6’s transmembrane domains 
results in the disruption of an exquisite spatial ar-
rangement of each domain, thereby altering the third 
loop’s structure.
　We have demonstrated that the 132fsX mutant 
offsets the 239fsX and the P299L mutants’ suppres-
sive effect on the R120G αBC mutant’s aggregation, 
and that neither the 173fsX nor the 243fsX mutant 
exhibits such compromising activity, proposing that 
clinical outcomes of patients compound heterozy-
gous for the 132fsX mutant and either the 239fsX 
or the P299L mutant are attributable to the loss of 
anti-aggregate activity. On the other hand, symp-
toms of patients with either homozygosity for the 
P299L mutant or compound heterozygosity for the 
P299L mutant and the 173fsX or the 243fsX mutant 
might be explained by CLN6’s functional defects 
unrelated to its anti-aggregate activity. Alternatively, 
the clinical manifestations of this group of patients 
would be ascribed to aggregation of CLN6’s physio-
logical targets. A caveat is that what we have deter-
mined so far is anti-aggregate activity toward the 
R120G αBC mutant, a model protein, but not that 
toward CLN6’s physiological target proteins. There-
fore, the prevention of the R120G αBC mutant’s ag-
gregation validated in HeLa cells transfected with 
the P299L mutant alone or together with the 173fsX 
or the 243fsX mutant, does not necessarily mean 
that every single CLN6’s physiological target is 
safeguarded against aggregation-inducing insults in 
patients harboring the P299L mutant alone or to-
gether with the 173fsX or the 243fsX mutant. We 
hence expect that the spectrum of CLN6’s physio-
logical targets remaining functional is different from 
patient to patient depending on which mutant or 
combination of CLN6 mutants each patient has, 
thereby giving rise to the symptom disparity. Patients 
with compound heterozygosity for the P299L and the 
173fsX mutants have been reported to present with 
visual impairment, a characteristic feature of late in-
fantile-onset CLN6 disease, whereas those with ho-
mozygosity for the P299L mutant not (Cannelli et 
al. 2009), arguing for our idea.
　Here we propose that the functional interference 
between coexisting CLN6 mutants is implicated in 
the development of CLN6 disease. Our findings pro-
vide novel insight into pathogenic mechanisms op-
erating in patients with compound heterozygosity 
for CLN6 mutants.
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mutant. We therefore suggested that CLN6’s luminal 
tail needs to be properly positioned for CLN6 to 
display its anti-aggregate activity and that the spatial 
constraint imposed on the tail is provided chiefly by 
Pro297 and Pro299. Of note, the P299L mutant was 
not disabled by the 173fsX or the 243fsX mutant. It 
would be that these two truncated mutants, unlike 
the 132fsX mutant, shield the P299L mutant’s re-
gion responsible for its anti-aggregate activity from 
access of its luminal tail. Meanwhile, the 239fsX 
mutant was compromised by the coexpressed 132fsX 
mutant despite the lack of the stretch of amino acids 
corresponding to CLN6’s luminal tail. It might be 
that an exquisite arrangement of seven transmem-
brane segments is indispensable for CLN6’s struc-
tural stability. Considering that Phe239 is predicted 
to be in the middle of CLN6’s sixth transmembrane 
segment (Sharp et al. 2003), the 239fsX mutant 
would be less rigid relative to wild-type CLN6. In 
consequence, the 132fsX mutant is likely to disturb 
the 239fsX mutant’s structure, thereby nullifying its 
anti-aggregate activity. Recently, a homozygous 
mutation in cat CLN6 has been reported, where a 
guanine to adenine change (c.668G>A) creates a ter-
mination codon at Trp 223 (pTrp223Ter) (Katz et al. 
2020). Like human CLN6, cat CLN6 is also predict-
ed to have seven transmembrane domains based on 
TMHMM, a membrane protein topology prediction 
program (http://www.cbs.dtu.dk/services/TMHMM/) 
and the Trp223 is situated in the fifth transmem-
brane domain (Supporting Fig. 1). A cat homozy-
gous for the c.668G>A mutation displayed clinical 
signs characteristic of the neuronal ceroid lipofusci-
noses, revealing that the protein product pTrp223Ter 
is a loss-of-function CLN6 mutant. Given that the 
239fsX human CLN6 mutant is prematurely termi-
nated in the sixth transmembrane domain, a pertur-
bation in CLN6 transmembrane domains is likely to 
affect the entire structure of CLN6 and in turn to 
impair its functionality.
　The third loop, predicted to face the ER lumen 
and also referred to as the second luminal loop, of 
CLN6 has been associated with ER-to-Golgi traf-
ficking of a spectrum of lysosomal enzymes (Bajaj 
et al. 2020). We previously demonstrated the re-
quirement for the third loop in CLN6’s anti-aggre-
gate activity (Yamashita et al. 2020). Based on the 
dysfunctionality of the pTrp223Ter cat CLN6 mu-
tant (Katz et al. 2020) and the vulnerability of the 
239fsX human CLN6 mutant to the 132fsX truncat-
ed mutant, the presence of the third loop itself is 
necessary but not sufficient for the full-fledged ac-
tivity of CLN6. It might be that a premature termi-
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